Showing results (2341-2350 of 2,545) with videos related to

Sort By:
Pageof 255
Breast Cancer Research and Treatment|March 9, 2005
Racial differences in the familial aggregation of breast cancer and other female cancersMichael S Simon, Jeannette F Korczak, Cecilia L Yee, et al.
Academic Pathology|August 18, 2017
The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient CareKaren L Kaul, Linda M Sabatini, Gregory J Tsongalis, et al.
Plos One|December 14, 2011
Genome-scale screen for DNA methylation-based detection markers for ovarian cancerMihaela Campan, Melissa Moffitt, Sahar Houshdaran, et al.
Journal of Pediatric Intensive Care|April 22, 2021
Practice Recommendations for Transcranial Doppler Ultrasonography in Critically Ill Children in the Pediatric Intensive Care Unit: A Multidisciplinary Expert Consensus StatementNicole Fortier O'Brien, Karin Reuter-Rice, Mark S Wainwright, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 22, 2025
An intranasally- and intramuscularly-deliverable nanostructured lipid carrier-replicon RNA vaccine drives protective systemic and mucosal immunityWynton D McClary, Devin S Brandt, Madeleine F Jennewein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
Journal of Comparative Effectiveness Research|December 23, 2015
Engaging stakeholders to design a comparative effectiveness trial in children with uncontrolled asthmaKim Erwin, Molly A Martin, Tara Flippin, et al.
Hematological Oncology|September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative statusMaika Onishi, Solomon A Graf, Leona Holmberg, et al.
Nature Communications|June 1, 2019
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Nature Communications|February 10, 2019
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Pageof 255